Trial Profile

A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axicabtagene ciloleucel (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell lymphoma
Focus Therapeutic Use
Acronyms ZUMA-14
Sponsors Gilead Sciences

Most Recent Events

06 Jun 2023 Results from NCT03391466, NCT03761056, NCT04002401, exploring the value of ctDNA to predict outcomes in LBCL after axi-cel across lines of treatment, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
10 Feb 2023 Status changed from active, no longer recruiting to completed.
23 Jun 2022 Planned End Date changed from 1 Jun 2036 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com